In this study, we designed and synthesized a non-radioactive iodinated, N-(3-{[2-({4-[4-acetylpiperazin-1-yl]-2-methoxyphenyl}amino)-5-(trifluoromethyl)pyrimidin-4-yl]amino}-5-iodophenyl)acrylamide (ICO1686, Scheme 1, 10) and a radioactive iodinated 10 ([125I]ICO1686, Scheme 2, [125I]10), and evaluated it using three types of human NSCLC cell lines—H1975 (dual mutations EGFR L858R/T790M), H3255 (EGFR L858R active mutant) and H441 (wild-type EGFR)—for use in selecting patients with NSCLC and predicting treatment strength of third-generation EGFR-TKIs. Here, EGFR is linked to non-small cell lung carcinoma.